With fresh $160M, RayzeBio plots sprint through the clinic for lead radiopharmaceutical program — building on Novartis success

Event Line

2022-09-15

Swiss competition watchdog probes Novartis over patent use

2022-09-15

Novartis says it is subject of Swiss competition probe

2022-09-14

Federal judge dismisses kickback claims in Novartis whistleblower case — again

2022-09-14

With fresh $160M, RayzeBio plots sprint through the clinic for lead radiopharmaceutical program — building on Novartis success

2022-09-14

Novartis to make $300m investment in next-generation biotherapeutics

2022-09-13

Novartis and BeiGene announce positive phase 3 trial results for hepatocellular carcinoma treatment

2022-09-13

Novartis invests in early technical development capabilities for next-generation biotherapeutics

2022-09-13

Novartis funnels $300M into early biologic drug manufacturing

2022-09-12

Novartis to invest $300mn in European biotherapeutics

2022-09-12

In the middle of an R&D shakeup, Novartis makes a $300M investment in early-stage biologics research tech

Expand more topics